**SUBJECT INDEX**

Note: Glossary is located on pages xviii–xix

<table>
<thead>
<tr>
<th>Term</th>
<th>Page(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Abbott PRISM system, 170–171</td>
<td></td>
</tr>
<tr>
<td>ABO incompatible transfusions, 307</td>
<td></td>
</tr>
<tr>
<td>Access immunoassay system, 171</td>
<td></td>
</tr>
<tr>
<td>acetate, human albumin safety, 264</td>
<td></td>
</tr>
<tr>
<td>acquired immunodeficiency syndrome (AIDS)</td>
<td></td>
</tr>
<tr>
<td>adsorption techniques, virus removal, 275–276</td>
<td></td>
</tr>
<tr>
<td>chromatography, 276</td>
<td></td>
</tr>
<tr>
<td>depth filtration, 275–276</td>
<td></td>
</tr>
<tr>
<td>adverse event/reactions, 366</td>
<td></td>
</tr>
<tr>
<td>Africa, blood safety, 372–376</td>
<td></td>
</tr>
<tr>
<td>costs, 375–376</td>
<td></td>
</tr>
<tr>
<td>organization, 373</td>
<td></td>
</tr>
<tr>
<td>transfusion-transmissible infections, 373</td>
<td></td>
</tr>
<tr>
<td>AIDS</td>
<td></td>
</tr>
<tr>
<td>toxoplasmosis, 125</td>
<td></td>
</tr>
<tr>
<td>transmission by plasma products, 263–264</td>
<td></td>
</tr>
<tr>
<td>risk management, 343–344</td>
<td></td>
</tr>
<tr>
<td>alanine aminotransferase (ALT), hepatitis viruses, 9, 196</td>
<td></td>
</tr>
<tr>
<td>albumin, human processing, 259, 275, 276</td>
<td></td>
</tr>
<tr>
<td>safety, 264–265</td>
<td></td>
</tr>
<tr>
<td>aspartate preparations, 264</td>
<td></td>
</tr>
<tr>
<td>Cohn fractions, 264</td>
<td></td>
</tr>
<tr>
<td>cold-ethanol fractionation, 265</td>
<td></td>
</tr>
<tr>
<td>HIV, 265</td>
<td></td>
</tr>
<tr>
<td>pasteurization, 264, 265, 271</td>
<td></td>
</tr>
<tr>
<td>algorithms, confirmatory testing see confirmatory algorithms</td>
<td></td>
</tr>
<tr>
<td>allogeneic transfusion, risk management, 335</td>
<td></td>
</tr>
<tr>
<td>American trypanosomiasis see Chagas’ disease</td>
<td></td>
</tr>
<tr>
<td>aminotransferase levels</td>
<td></td>
</tr>
<tr>
<td>hepatitis B virus, 14</td>
<td></td>
</tr>
<tr>
<td>hepatitis C virus, 17</td>
<td></td>
</tr>
<tr>
<td>amotosalen (S59), 247–249</td>
<td></td>
</tr>
<tr>
<td>fresh frozen plasma treatment, 250</td>
<td></td>
</tr>
<tr>
<td>clinical studies, 252</td>
<td></td>
</tr>
<tr>
<td>reduction factors, 246</td>
<td></td>
</tr>
<tr>
<td>platelet treatments, 247–249</td>
<td></td>
</tr>
<tr>
<td>amplicons, polymerase chain reaction contamination, 187</td>
<td></td>
</tr>
<tr>
<td>detection, 184–185</td>
<td></td>
</tr>
<tr>
<td>Amplicore extraction system, 213</td>
<td></td>
</tr>
<tr>
<td>amplification</td>
<td></td>
</tr>
<tr>
<td>microarrays, 232</td>
<td></td>
</tr>
<tr>
<td>nucleic acids see specific techniques</td>
<td></td>
</tr>
<tr>
<td>Amplicore extraction system, 213</td>
<td></td>
</tr>
<tr>
<td>extraction performance, 212</td>
<td></td>
</tr>
<tr>
<td>protocol, 214</td>
<td></td>
</tr>
<tr>
<td>Andean Countries Initiative, Chagas’ disease, 128</td>
<td></td>
</tr>
<tr>
<td>animal models, cytomegalovirus, 49</td>
<td></td>
</tr>
<tr>
<td>anion exchange chromatography, 276</td>
<td></td>
</tr>
<tr>
<td>Anopheles mosquitoes, 117, 118</td>
<td></td>
</tr>
<tr>
<td>antibodies, monoclonal, 277</td>
<td></td>
</tr>
<tr>
<td>antibody capture assays, 164</td>
<td></td>
</tr>
<tr>
<td>antibody detection, 227–228</td>
<td></td>
</tr>
<tr>
<td>cytomegalovirus, 159</td>
<td></td>
</tr>
<tr>
<td>false-negative tests, 312–313</td>
<td></td>
</tr>
<tr>
<td>hepatitis C virus, 162</td>
<td></td>
</tr>
<tr>
<td>residual window period, 227</td>
<td></td>
</tr>
<tr>
<td>syphilis, 169</td>
<td></td>
</tr>
<tr>
<td>antibody mediated virus neutralization, fractionated products, 274, 284</td>
<td></td>
</tr>
<tr>
<td>anti-D, hepatitis C transmission, 266</td>
<td></td>
</tr>
<tr>
<td>anti-E2, GB virus C/hepatitis G virus, 76</td>
<td></td>
</tr>
<tr>
<td>antigen(s)</td>
<td></td>
</tr>
<tr>
<td>recombinant, 227</td>
<td></td>
</tr>
<tr>
<td>sandwich assays, 162–163</td>
<td></td>
</tr>
<tr>
<td>antiglobulin test(s), 227</td>
<td></td>
</tr>
<tr>
<td>antiglobulin tests, 162</td>
<td></td>
</tr>
<tr>
<td>anti-HAV, 11</td>
<td></td>
</tr>
<tr>
<td>anti-HV, 17</td>
<td></td>
</tr>
<tr>
<td>screening, 9, 175, 204</td>
<td></td>
</tr>
<tr>
<td>anti-HIV tests, 162</td>
<td></td>
</tr>
<tr>
<td>kit comparisons, 165</td>
<td></td>
</tr>
<tr>
<td>p24 antigen, 160</td>
<td></td>
</tr>
<tr>
<td>apheresis, 249</td>
<td></td>
</tr>
<tr>
<td>platelet concentrations, 94, 95</td>
<td></td>
</tr>
<tr>
<td>Architect immunoassay system, 170</td>
<td></td>
</tr>
<tr>
<td>archived blood samples, 312</td>
<td></td>
</tr>
<tr>
<td>Asia, blood safety, 368–372</td>
<td></td>
</tr>
<tr>
<td>blood procurement, 370</td>
<td></td>
</tr>
<tr>
<td>transfusion-transmitted infections, 370–372</td>
<td></td>
</tr>
<tr>
<td>assay(s)</td>
<td></td>
</tr>
<tr>
<td>closed systems, 222</td>
<td></td>
</tr>
<tr>
<td>design, 219–220</td>
<td></td>
</tr>
<tr>
<td>process control, 220</td>
<td></td>
</tr>
<tr>
<td>reagent presentation, 219</td>
<td></td>
</tr>
<tr>
<td>repeat tests, 165, 219</td>
<td></td>
</tr>
<tr>
<td>sample incubation, 220</td>
<td></td>
</tr>
<tr>
<td>sample volumes, 219</td>
<td></td>
</tr>
<tr>
<td>usability, 219–220</td>
<td></td>
</tr>
<tr>
<td>evaluation, 220–221</td>
<td></td>
</tr>
<tr>
<td>operational, 221</td>
<td></td>
</tr>
<tr>
<td>parameters, 228–231</td>
<td></td>
</tr>
<tr>
<td>minimal detectable limits, 282</td>
<td></td>
</tr>
<tr>
<td>nucleic acid testing, 200</td>
<td></td>
</tr>
<tr>
<td>extraction, 211</td>
<td></td>
</tr>
<tr>
<td>screening quality, 222</td>
<td></td>
</tr>
<tr>
<td>staff knowledge/skills, 225–226</td>
<td></td>
</tr>
<tr>
<td>avian influenza, 84</td>
<td></td>
</tr>
<tr>
<td>Autologous blood transfusion, 353</td>
<td></td>
</tr>
<tr>
<td>donor bacteremia, 88</td>
<td></td>
</tr>
<tr>
<td>EU definition, 366</td>
<td></td>
</tr>
<tr>
<td>automation</td>
<td></td>
</tr>
<tr>
<td>blood cultures, 98–100</td>
<td></td>
</tr>
<tr>
<td>calibration, 222</td>
<td></td>
</tr>
<tr>
<td>enzyme linked immunosorbent assays, 165–166</td>
<td></td>
</tr>
<tr>
<td>limitations, 222</td>
<td></td>
</tr>
<tr>
<td>maintenance, 222</td>
<td></td>
</tr>
<tr>
<td>nucleic acid testing, 200</td>
<td></td>
</tr>
<tr>
<td>extraction, 211</td>
<td></td>
</tr>
<tr>
<td>screening quality, 222</td>
<td></td>
</tr>
<tr>
<td>Austria antigen see hepatitis B virus</td>
<td></td>
</tr>
<tr>
<td>autoclaving, 287</td>
<td></td>
</tr>
<tr>
<td>Babesia, 122–125</td>
<td></td>
</tr>
<tr>
<td>characteristics, 123</td>
<td></td>
</tr>
<tr>
<td>endemic areas, blood collection avoidance, 124</td>
<td></td>
</tr>
<tr>
<td>historical aspects, 122</td>
<td></td>
</tr>
<tr>
<td>immunodetection assay, 123</td>
<td></td>
</tr>
<tr>
<td>life cycle, 122</td>
<td></td>
</tr>
<tr>
<td>nucleic acid testing, 123</td>
<td></td>
</tr>
<tr>
<td>prevalence studies, 123</td>
<td></td>
</tr>
<tr>
<td>risk factors, 124</td>
<td></td>
</tr>
<tr>
<td>seroprevalence studies, 124</td>
<td></td>
</tr>
<tr>
<td>transfusion-transmitted, 124</td>
<td></td>
</tr>
<tr>
<td>Babesia microti, 123</td>
<td></td>
</tr>
<tr>
<td>babesiosis, 122–125</td>
<td></td>
</tr>
<tr>
<td>diagnosis, 123</td>
<td></td>
</tr>
<tr>
<td>‘gold standard’ test, 123</td>
<td></td>
</tr>
<tr>
<td>human infection, 123</td>
<td></td>
</tr>
<tr>
<td>transmission, 122</td>
<td></td>
</tr>
<tr>
<td>BacT/ALERT System, 98–100</td>
<td></td>
</tr>
<tr>
<td>bacterial detection algorithm, 100</td>
<td></td>
</tr>
<tr>
<td>bacterial screening data, 101</td>
<td></td>
</tr>
<tr>
<td>Pall eBDS system vs., 101, 102</td>
<td></td>
</tr>
</tbody>
</table>
Subject index

bacteria, blood/blood components contamination, 87–115
arm-derived, 87
improvement strategies, 91–92
blood processing defects, 89
blood storage/processing, 93–94
contaminated collection equipment, 88–89
endotoxin detection, 97
growth kinetics, 95
leucocyte depletion, 241
metabolic changes, 104
microscopic examination, 97
molecular detection, 97
organisms, 88–90, 91
post-transfusion infection investigations, 314
prevalence, 89
recipient exposure reduction, 94
red cell inactivation systems, 107–109
reduction strategies, 91–94, 244
donor selection, 91
improved donor arm disinfection, 91, 92
screening, 94–106
cellular system, 98–100
cell wall detection, 105
challenges in, 94–95
culture techniques, 98
issues, 95–96
platelet concentrates, 95
rapid techniques, 102–103
sources, 87–89
transfusion reaction prevalence, 90
visual detection, 96
bacterial cell wall detection assay, 105
Bacterial contamination of Blood (BaCon), 89
Better Blood Transfusion (1998), 306
Better Blood Transfusion (2002), 306
bilirubin levels, hepatitis, 14
Better Blood Transfusion (2005), 305
BioMérieux culture bottles, 99
BioMérieux assay, 89–91
BioMérieux culture bottles, 99
biosensors, 228–230
bisexual men, HIV risk, 62
blood
donation volume, 153
EU definition, 366
blood component(s)
contaminated equipment, 88–89
definition, 366
European Union legislation, 365
blood culture(s)
automated systems, 98–100
bottle manufacture, 99
blood donor(s)
bacterial contamination see bacteria, blood/blood components contamination
health risks, 156
herpes virus screening, 52
non-living, 328
pathogen reduction see pathogen reduction (PR)
positive test result notification, 317–321
confidentiality, 318
contact planning, 318
documentation, 319
donor discussion, 319
falsely reactive results, 320
history, 317
HIV, 317, 318
indeterminate results, 320
management, 317
non-living donors, 320
objectives, 318
referrals, 319, 320
response initiatives, 318
staff training, 319
qualification, 153–157
recruitment process, 153–154
re-admission see donor re-admission
registers, 154
registration, 155–157
replacement, 154, 370
selection, 153–157, 352
criteria, 155–156
donor health damage risk, 155–156
guidelines, 155, 157
principles, 153
screening quality, 217, 218, 225
social considerations, 157
transfusion-transmissible infections, 156–157
blood establishment, definition, 366
blood, frozen, transfusion-transmission infection, 52
blood grouping analysers, 167–168
blood pressure, donor physical examination, 155
blood product, EU definition, 366
donor health damage risk, 155–156
infection, 52
screening, 130
serological tests issues, 131
transfusion transmission
case underestimation factors, 129
historical aspects, 128
prevention strategies, 130
see also Trypanosoma cruzi
chemiluminescence, hepatitis B surface antigen, 14
Chikungunya fever virus (CHIKV), 1, 7
children, hepatitis B virus infection, 13
Chor Procras system (instrumentation) detection limits, 210
nucleic acid testing, 209
chlorhexidine alcohol, 92
chloroform, 272
chromatography column contamination, 266
prion removal, 287
virus removal, 276
chronic wasting disease (CWD), 141
closed system assays, 222
Clostridium perfringens, 87
clothing/coagulation factor(s) activation, 256–267
congenital deficiency, 44
leucocyte depletion effects, 241
levels, 250
parvovirus B19 transmission, 264
plasma treatment effects, 250–251
inhibitors, 251
virus transmission, 259, 269
coaulation factors see clotting/coagulation factor(s)
CORAS Ampliscreen HIV test, 29
Cohn, Edwin Joseph
fractionation, 282, 284, 285, 275
haemophilia treatment, 267
hepatitis transmission, 275
cold-ethanol fractionation, 265
combi assays see combination assays
combination assays see combination assays(2), 60, 164, 228
HAV p24 antigen testing, 164
syphilis testing, 164
Committee for Proprietary Medicinal Products (CPMP), 183, 278
nucleic acid testing, 193, 209
risk assessments, 283
competent authorities, European Union legislation, 366
competitive immunoassays, 163–164
confidentiality, European Union legislation, 366–367
Chagas’ disease, 128–131
blood component infection, 129
blood donor grouping, 130
chronic, 129
crystal violet treatment, 130, 131
clinical features, 130
CMV serology testing, 128
detection methods, 131
epidemiology, 128
history, 128
incubation period, 130
phases, 130
prevalence, 129
prevention strategies, 130
’safety Tripod’ concept, 132
natural products testing, 130
safety Tripod’ concept, 132
screening, 130
serological tests issues, 131
transfusion transmission
case underestimation factors, 129
historical aspects, 128
prevention strategies, 130
see also Trypanosoma cruzi
chemiluminescence, hepatitis B surface antigen, 14
Chikungunya fever virus (CHIKV), 1, 7
children, hepatitis B virus infection, 13
Chor Procras system (instrumentation) detection limits, 210
nucleic acid testing, 209
chlorhexidine alcohol, 92
chloroform, 272
chromatography column contamination, 266
prion removal, 287
virus removal, 276
chronic wasting disease (CWD), 141
closed system assays, 222
Clostridium perfringens, 87
clothing/coagulation factor(s) activation, 256–257
congenital deficiency, 44
leucocyte depletion effects, 241
levels, 250
parvovirus B19 transmission, 264
plasma treatment effects, 250–251
inhibitors, 251
virus transmission, 259, 269
coaulation factors see clotting/coagulation factor(s)
CORAS Ampliscreen HIV test, 29
Cohn, Edwin Joseph
fractionation, 282, 284, 285, 275
haemophilia treatment, 267
hepatitis transmission, 275
cold-ethanol fractionation, 265
combi assays see combination assays
combination assays see combination assays(2), 60, 164, 228
HAV p24 antigen testing, 164
syphilis testing, 164
Committee for Proprietary Medicinal Products (CPMP), 183, 278
nucleic acid testing, 193, 209
risk assessments, 283
competent authorities, European Union legislation, 366
competitive immunoassays, 163–164
confidentiality, European Union legislation, 366–367
confirmatory algorithms, 173–177, 236–237
BacT/ALERT, 100
hepatitis B virus, 174
hepatitis C virus, 174–176
HIV, 176
syphilis, 176
technology, impacts on, 236–237
confirmatory testing (screening), 173–180
algorithms see confirmatory algorithms
confirmed infection rate, 180
importance, 181
inconclusive results, 176–179
atypical patterns, 178, 179
spurious blot/line assay bands, 177
leucocytes, 177
levels, 174
limitations, 173–174
principles, 173–174
congenital coagulation factor deficiency, 344
consumer protection, European Union legislation, 366–367
contact spotting, microarray technology, 232
contamination controls, nucleic acid testing, 187–188
equipment, blood/blood components, 88–89
prion removal, 287
cost-effectiveness (CE) analysis regulatory requirements, 358
risk management, 356–357, 358
transfusion safety interventions, 357–359
Council of Europe (CoE), 364
European Union distiction, 363–364
haemoglobin levels, 155
haemovigilance, 305
leucocyte depletion, 239
voluntary non-renumerated donors, 153
Creutzfeldt–Jakob disease (CJD)
blood product management, 147
familial, 142, 143
pathophysiology, 143
sporadic, 141, 143
tissue product management, 147
variant see variant Creutzfeldt–Jakob disease (vCJD)
cryoprecipitate production, 252
haemophilia treatment, 267–268
crystal violet, Chagas’ disease, 130, 131
cytomegalovirus (CMV), 4–5, 35–50
animal models, 49
breakthrough infections
seronegative patients, 47–48
WBC reduction components, 47–48
characteristics, 4–5, 35–36
detection tests, 37–39
antibody screening, 37–38, 159, 163
antigen detection, 39
molecular amplification, 39
viral culture, 39
disease definition, 43
DNA detection, 38–39
immunosuppression, 240
infected blood, transmission, post-storage filtration, 240
leucocyte depletion, 239–241
neonatal infection, exchange transfusion, 41
nucleic acid testing, 197
pathogen reduction, 244, 246
prestorage WBC reduction, 42
primary infection, 240
reactivation, allogeneic transfusion, 49–50
seroconversion, 35, 36, 39
transfusion-acquired infection
animal models, 41
blood donor associations, 40–41
clinical manifestations, 36–37
non-white blood cell components, 39–42
seronegative patients, 43–48
transfusion recipient associations, 42
transfusion recipient associations, 42
unscreened components, 39–42
white blood cell reduced components, 43–48
deglycerolized blood, transfusion-transmission infection, 52
delta virus see hepatitis D virus
Department of Health (DoH), plasma fractionation restrictions, 209
depth filtration
prion removal, 287
virus removal, 275–276
developing countries, blood safety, 369–380
developed vs developing countries, 369
prevalence, 369
see also individual countries/continents
diagnostics
microarrays see microarrays
see also specific assays
diabetes mellitus, 223–224
blood donation testing, European Union legislation, personnel, 366
European Union Directives
2001/83/EC, medicinal products, 364–365
2003/94/EC, medicinal products, 365
2004/23/EC, tissues, 365
2004/33/EC, blood/blood components, 367
2004/33/EC, tissues, 365
2006/17/EC, tissues, 365
definitions, 366
implementation, 367
European Union legislation, personnel, 366
Europe, regulatory environment see regulatory environment, Europe
EuroSPRITE clinical study, 248
external quality assessment schemes (EQAS), 223–224
extraction systems, Amplicore, 213
383
Subject index

factor VIII
  haemophilia treatment, 267–270
  hepatitis transmission, 11, 12, 270
  history, 267–270
HIV transmission, 272
  inhibitors, 269, 271
  ion exchange purification, 277
methylene blue fresh frozen plasma treatment, 250
  stabilisation, 270–271
factor IX, thrombogenicity, 272
Fernandes, Pete, factor VIII stabilization, 271
false-negative antibody tests, 312
fifth disease, parvovirus B19, 68, 69
  natural history, 75–76
  pathogenicity, 77
  HIV infection, 77
  in transfusion, 76–77
  transmission, 76
Fukuoka I strain, 144
FVIII stabilisation, 270–271
Gammagard SD, 266–267
GB virus C/hepatitis G virus (GBV-C/HGV), 75–77, 263
  characteristics, 75
  coinfections, 75
  diagnosis, 77
  genotypes, 75
  geographic distribution, 76
  HIV infection, 77
  infection risk factors, 11
  infection, 271
  life cycle, 10
  nucleic acid testing, 196–197
  United States approach, 206–207
  vaccine transmitted, 262
  venereal transmission, 12
  outbreaks, 12
  transmission, 344
  fractional products, 263
  solvent detergent treated products, 273–274
  vaccines, 12
  viraemia duration, 207
  window period, 11
  hepatitis B core antibody (anti-HBc), 169
  anti-HBC vs. anti-HBs, 161
  hepatitis B core antigens antibody (anti-HBc) see anti-HBc
  hepatitis B e-antigen (HBeAg), 13
  hepatitis B surface antibody see anti-HBs
  hepatitis B surface antigen (HBsAg), 13, 25, 161
  absence
  anti-HBC issues, 26–29
  hepatitis B virus issues, 26–29
  anion exchange chromatography, 276
  blood donation screening, 14
  confirmatory algorithms, 174, 175
  diagnostic testing, 14
  risk assessment calculation, 332
  screening, 14, 228
  anti-HBs vs. anti-HBc, 161
  enzyme linked immunosorbent assay, 160
  kit test comparisons, 165
  nucleic acid testing vs. antigen tests, 195
  reverse passive haemagglutination assay, 167–169
  hepatitis B virus (HBV), 12–16
  acute infection, 13–14
  diagnosis, 14
  inapparent, 313
  jaundice, 13
  anti-HBC presence, 26–29
  anti-HBs absence, 26–29
hepatitis C virus (HCV), 16–19, 267
hepatitis C antigen (HCVAg), 17, 18
see also associated antigens
characteristics, 12–13
definition, 12–13
detection limits, 195
diagnostic testing, 14–15, 313
DNA, 25
DNA studies, 27, 30
donor re-admission, 180
escape mutants, 161
extrahapatic complications, 13
fractionated products, removal, 275
genome, 13
HDV coinfection see hepatitis B virus
risk factors, 15
definition, 19
diagnostic testing, 19–20
risk factors, 20
seroprevalence rate, 19
window period, 20
hepatitis G virus (HGV) see GB virus C/hepatitis G virus (GBV-C/HGV)
hepatocellular carcinoma (HCC), hepatitis B virus, 13
hepatocyte, hepatitis effects, 10, 17, 19
herpes viruses, 35–58
human pathogens, 36
see also specific virus
high throughput automated assay, 210
HIV
blood donors
positive result notification, 317
re-admission, 181
fractionated products, removal from
ethanol fractionation, 275
immunoaffinity chromatography, 276
nanofiltration, 276
GB virus C/hepatitis G virus coinfection, 77
human albumin safety, 265
immunoglobulin(s), intravenous treatment
immunoassay systems, 169–171
immunofluorescence assay (IFA), KSHV
immunoassay systems, 169–171
immuno-polymerase chain reaction, prion
immunoassay systems, 169–171
Kaposi’s sarcoma-associated herpes virus (KSHV)
detection, 78
immunoglobulin(s), intravenous treatment see
intravenous immunoglobulin (IVIg) treatment
immunoglobulin M (IgM) anti-HAV measurement, 11
babesial infections, 123
CMV infection, 38
detection, 161
immuno-polymerase chain reaction, prion
diseases, 150
immunosuppression, cytomegalovirus
infection, 240
inactivator (PE110), 253
clinical studies, 247
red cell treatment, 107
incorrect blood component transfused' (IBCT), 307, 308
indicators, chemical screening, 220
indirect haemagglutination, Chagas’ disease, 131
indirect immunofluorescence assay (IFAT)
babesial infections, 123
Chagas’ disease, 131
infection(s) see post-transfusion infection investigation
infectious agents, new/emerging, 5
‘infected hepatitis,’ 262
Subject index

influenza virus, 84
avian, 84
Innolia III, 175
intercept system, 108
platelet concentrate reduction, 106–107
internal quality assessment (IQA), 224
International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH)
(1998), 246
intravenous immunoglobulin (IVIg) treatment
hepatitis transmission, 265, 266
nanofiltration, 277
pepsin, 274
preparation methods, 265, 275, 276
safety, 265–267
hepatitis C transmission, 266–267
history, 265–266
HIV transmission, 266
low pH treatment, 274
ion exchange chromatography, 276
Irish Blood Transfusion Service (IBTS), 31
Ixodes ricinus, 122, 123
Ixodes scapularis, 122
Ixodes ticks, 122
jaundice
hepatitis B virus, 13
hepatitis C virus, 17
Kala-azar, 127
Kaposi’s sarcoma-associated herpes virus (KSHV), 52–54, 77–80
characteristics, 77–78
CMV coexistence studies, 54
detection methods, 77, 78
endemicity, 53
epidemiology, 78–79
genomic organization, 77
HIV infection, 78
absence, 54
multiple myeloma, 78, 79, 80
seroconversion risk, seronegative vs. seropositive blood, 53
seroconversion rates, 53
transplantation, 79
kidney transplantation, 79
kinetic polymerase chain reaction (KPCR), 185
Koate® concentrate, 268, 271
KSHV see Kaposi’s sarcoma-associated herpes virus (KSHV)
Kuru, 141, 142
labile protein pasteurization, 270–271
laboratory staff
confidentiality, 319
knowledge/skills, 225–226
training, 228, 319
latex particles, particle agglutination assays, 167
Latin America, blood safety
costs, 376–378
demographics, 378
infectious disease markers prevalence, 376
transfusion services structure, 377
transfusion-transmissible infections, 377–378
Leishmania, 126–128
life cycle, 126
stored blood components, parasite survival, 127
transfusion-transmitted, 127
military cases, 127
Leishmaniasis, 126–128
sero logical tests, 127
leucocyte depletion (LD), 239–241
bacteria, 241
benefits, 239
component quality effects, 241
cytomegalovirus, 239–241
filters, 94
human T-cell leukaemia viruses, 241
prion removal, 241
specifications, 239
variant Creutzfeldt-Jakob disease (vCJD), 241
Liberate®, 277, 278
ligase chain reaction (LCR), 186, 187
low pH treatments, 282
liver
biopsies, 326
SEN virus replication, 81
liver failure, hepatitis B, 13
look-back investigations, 314–315
Creutzfeldt-Jakob disease (CJD), 344
infection rates vs. clinical outcomes, 350
lot release, screening quality, 221–222
low pH treatment
immunoglobulin safety, 274
parvovirus B19, 282
virus inactivation processes, 274
viruses validation studies, 282
Luc, Murray, 264
malaria, 117–122, 159
blood components, 119–122
donor questioning, 119–121
immigrants, 119
regulations, 119
remote endemic area recommendations, 120
screening problems, 120
post-transfusion infection investigation, 131
screening tests, 308
seroconversion risk, seronegative vs. seropositive blood, 53
seroconversion rates, 53
transplantation, 79
measles, 364–365
minimal deferral period, donor re-admission, 180
hemorrhage, 279
microarrays, 229–233
malaria, 117–122, 159
blood components, 119–122
donor questioning, 119–121
immigrants, 119
regulations, 119
remote endemic area recommendations, 120
screening problems, 120
post-transfusion infection investigation, 131
screening tests, 121–122
Viennese blood donor findings, 122
transfusion-transmitted see transfusion-transmitted malaria (TFM)
malignancy, blood donor selection criteria, 157
medicinal product legislation, European Union, 364–365
metabolomics, 229
methylene blue fresh frozen plasma (MBFFP), 249–250
clinical studies, 251–252
clotting factor levels, 250
microarrays, 229–233
benefits, 232
carbohydrate, 233
cell, 233
contact screening, 232
design features, 230–232
DNA, 232–233
probes, 230
fluorescent detection, 232
multiple formats, 230–232
pathogen detection, 233–236
PCR and, 233
sensitivity, 232, 235
signal amplification methods, 232
substrates, 230
Microbiology in Blood Transfusion, 1
microarrays, 276
microvolume fluorimetry, 104–105
minimal deferral period, donor re-admission, 180
Mirasol system, platelet concentrate reduction systems, 107
misfolded protein diagnostic (MPD) assay, prion diseases, 149
monoclonal antibodies, production validation, 277
mortality, 351
mosquitoes, 117
multicentre Casemzeman’s disease (MCD), KSHV sequences, 78
multimer detection system, prion diseases, 150
multiple myeloma, KSHV, 78, 79, 80
‘multiple spotting technique’ (MIST), microarray technology, 236
multiplex PCRs, nucleic acid testing, 189, 198, 229, 233, 235
NANR hepatitis see hepatitis C virus (HCV)
nanocrystals, microarray sensitivity, 232
nanofiltration
prion removal, 286, 290
virus removal, 276–277
National Blood Service (UK), 209
archived samples, 312
assay evaluation, 221
blood donors positive results, 317
high throughput automated assays, 210
post-transfusion infection investigation, 311
staff, 319
National CJD surveillance Unit (NCJDSU), 144, 145
National Blood Microbiology Clinical Group, 317
‘near miss’ data collection, 308
neonatals, 247
neonates
cytomegalovirus infection, exchange transfusion, 119
hepatitis B infection, 13
New York Blood Center (NYBC), solvent detergent treatment, 272
nitrogen mustard, 270
non-A, non-B (NANB) hepatitis virus, 9, 267, 274
non-haematological disease, parvovirus B19, 68
non-lipid-enveloped viruses, 249, 280
non-living donors, 328
nucleic acid sequence based amplification (NASBA), 186
nucleic acid testing (NAT), 183–201, 228
amplifier detection, 211
amplification, 211
Ampliscreen system see Ampliscreen system anti-HBc coupling, 204–205
applications strategy, 183–191
assay requirements, 210–215
automated extraction, 213
automation, 200
contamination, 187–188
controls, 188

386
Subject index

cost, 183
cytomegalovirus, 197
data handling, 211
diagnostic windows, 194, 203
efficiency, 199–200
enhanced testing vs. pathogen inactivation, 200
extraction volumes, 199
hepatitis B virus, 15, 16
hepatitis C virus, 215
historical aspects, 18
microarray vs., 232
multiplexing, 189, 198, 229, 233, 235
negative results, 184
nucleic acid extraction, 184
parallel testing, 200
performance monitoring, 221, 213, 215
polymerase chain reaction see polymerase chain reaction (PCR)
residual transmission risks, 193–194, 200, 203
reverse transcription, 211
risk assessment calculation, 338
robustness, 189
safety issues, 228
sample pooling, 188–189, 194–197, 210
sample testing, 216–211
sample volume, 193
screening options, 233, 235
sensitivity, 184, 193, 198–199, 261
specificity, 198–199
strategy, 209–210
system controls, 211
system monitoring, 211, 212, 213, 215
Pulse Management Software, 211
testing strategies, 197–198
throughput, 199
United Kingdom, 209–215
United States, 203–207
Western blot vs., 203
West Nile virus, 83
see also specific techniques
occupation, transfusion-transmissible infection, 156
oligosaccharide microarrays, 233
Oliphant, J.W, 270
Olympus PK7200 blood grouping analyser, 167–168
open system assays, 222, 225
operational evaluation, assays, 221
Paling perspective scale, 356
Pall eBDS system, 100–102
BacT/ALERT vs., 102
Pan American Health Organization (PAHO)
blood bank numbers, 377
Chagas’ disease, 128
‘paper’ evaluation, assays, 221
parasites
pathogen reduction, 254
post-transfusion infection investigation, 313
particle agglutination assay(s), 166, 219
carbon particles, 166
haemagglutination tests see haemagglutination test(s)
latex particles, 167
Pavloviviridae, 67, 71
parvovirus B19 (B19V), 67–73
characteristics, 67
definition, 67
genome, 67
genotypes, 67
inactivation, 281–282
infection
fetal, 69
incidence, 196, 197, 206
pregnancy, 264
prevention, 69–70
vaccine development, 69, 70
pathogen detection, 233–236
pathogen inactivation (PI), transfusion-transmitted
HCV, 19
pathogen reduction (PR), 106–109, 242–254
approaches, 242, 243
cost effectiveness, 254
cytomegalovirus transmission prevention, 244, 246
development systems, 106–107
donor selection issues, 254
health and safety, 254
methods, 243, 247–254
neutropenia, 247
parasite inactivation, 254
post-illumination, 242, 243, 246
process control, 254
quality assurance, 254
reduction factors, 244
toxicity, 246–247
transfusion-associted graft-vs.-host disease, 254
viral titres, 242, 244
PEN110 (maclure), 253
clinical trial cessation, 247
red cell treatment, 108, 109
pepsin, immunoglobulin treatment, 274
peptidoyl assay, prion diseases, 149
perinatal transmission, hepatitis B virus, 12
persistent reactivity, 179
personnel, European Union legislation, 366
pH
bacterial contamination, 184
low pH treatment see low pH treatment
photo-inactivation technology, pathogen reduction, 242
photomask-determined synthesis, microarray technology, 252
planar waveguide technology, microarray sensitivity, 232
plasma fractionation, 259–262
European regulations, 278
HIV, 278
nucleic acid testing, 183
poor, 261
processes, 261–262
products, 260
restrictions, 209
viruses, 260, 279
see also virus inactivation
voluntary non-renumerated blood donors, 153–154
Plasmodium, 117–122
blood components, 119–122
life cycle, 117
screening, 121–122
Plasmodium falciparum, 117, 118, 119, 122
Plasmodium malariae, 117, 119
Plasmodium ovale, 117, 119
Plasmodium vivax, 117, 119
platelet concentrate reduction systems, 106–107
intercept system, 106–107
Miraxel system, 107
platelet screening, 101
platelet treatments, pathogen reduction systems, 247–249
polyethylene glycol (PEG) precipitation, 275
polymerase chain reaction (PCR), 228
amplification, 184–185
Chagas’ disease, 131
contamination, 198
cytomegalovirus, 38–39
history, 184
malarial screening, 122
microarray combination testing, 233
prion diseases, 150
real time, 183
reverse transcription, 184
screening options, 233, 235
sensitivity, 198
polyneuropathy, organomegaly, endocrinopathy, M
protein and skin changes (POEMS), 78
post-illumination, pathogen reduction, 242, 243, 246
post-transfusion infection investigation, 311–315
bacterial infections, 314
compensation, 315
documentation systems, 315
look-back investigations, 313
non-bacterial agents, 311–312
patient details required, 312
see also specific infections
precipitation
prion removal, 287
virus removal, 275
precision plots, 224–225
pregnancy
CMV infection study, 41
parvovirus B19, 69
prion(s), 285–290
fractionation investigation studies, 286–287, 290
removal techniques, 241, 287, 288, 290
prion diseases, 141–151
bovine spongiform encephalopathy, 141
chronic wasting disease, 141
kuru, 141, 142
molecular basis, 142–143
follicular dendritic cells, 142
human PrP, 142
### Subject index

<table>
<thead>
<tr>
<th>prion diseases (cont.)</th>
<th>PRNP gene, 142</th>
</tr>
</thead>
<tbody>
<tr>
<td>PrP, 142, 143</td>
<td></td>
</tr>
<tr>
<td>PrP *, 142, 144</td>
<td></td>
</tr>
<tr>
<td>PrP ** see PrP*</td>
<td></td>
</tr>
<tr>
<td>pathophysiology, 143–144</td>
<td></td>
</tr>
<tr>
<td>peripheral blood infectivity</td>
<td></td>
</tr>
<tr>
<td>animal models, 144</td>
<td></td>
</tr>
<tr>
<td>blood transmission risk, 144–145</td>
<td></td>
</tr>
<tr>
<td>tissue products, 144–145</td>
<td></td>
</tr>
<tr>
<td>scrapie, 141, 142, 144</td>
<td></td>
</tr>
<tr>
<td>sporadic CJD see Creutzfeldt-Jakob disease (CJD) testing, 148–149</td>
<td></td>
</tr>
<tr>
<td>transmissible mink encephalopathy, 141</td>
<td></td>
</tr>
<tr>
<td>transmission risk management strategies, 145–147</td>
<td></td>
</tr>
<tr>
<td>blood component processing, 147</td>
<td></td>
</tr>
<tr>
<td>cell products, 147</td>
<td></td>
</tr>
<tr>
<td>diagnostic/screening peripheral blood assay development, 146–147</td>
<td></td>
</tr>
<tr>
<td>donor selection, 146</td>
<td></td>
</tr>
<tr>
<td>outsourcing blood/tissue practicalities, 146</td>
<td></td>
</tr>
<tr>
<td>plasma products, 147</td>
<td></td>
</tr>
<tr>
<td>tissue products, 147</td>
<td></td>
</tr>
<tr>
<td>variant CJD see variant Creutzfeldt-Jakob disease (vCJD)</td>
<td></td>
</tr>
<tr>
<td>PRNP gene, 142</td>
<td></td>
</tr>
<tr>
<td>probability assignment, risk management, 132</td>
<td></td>
</tr>
<tr>
<td>process control, 217</td>
<td></td>
</tr>
<tr>
<td>assay design, 220</td>
<td></td>
</tr>
<tr>
<td>pathogen reduction, 254</td>
<td></td>
</tr>
<tr>
<td>validation, 224</td>
<td></td>
</tr>
<tr>
<td>Procleix TMA assay, 189, 209, 210</td>
<td></td>
</tr>
<tr>
<td>product safety margins, 246–247, 247</td>
<td></td>
</tr>
<tr>
<td>protein microarrays, 231</td>
<td></td>
</tr>
<tr>
<td>protein misfolding cyclic amplification (PMCA), 149</td>
<td></td>
</tr>
<tr>
<td>protein precipitation, 275</td>
<td></td>
</tr>
<tr>
<td>proteomics, 228, 233</td>
<td></td>
</tr>
<tr>
<td>prion protein complex concentrates (PCC), 277</td>
<td></td>
</tr>
<tr>
<td>prionotasis parasites, 117–139</td>
<td></td>
</tr>
<tr>
<td>see also specific disease(s)</td>
<td></td>
</tr>
<tr>
<td>PrP, 142, 143</td>
<td></td>
</tr>
<tr>
<td>PrP *, 142, 144</td>
<td></td>
</tr>
<tr>
<td>human, 142</td>
<td></td>
</tr>
<tr>
<td>PrP ** see PrP*</td>
<td></td>
</tr>
<tr>
<td>PrP **, 142, 146</td>
<td></td>
</tr>
<tr>
<td>diagnostic tests, 149, 150</td>
<td></td>
</tr>
<tr>
<td>immunoaasay, 141</td>
<td></td>
</tr>
<tr>
<td>Pulse Management Software (PMS), 211</td>
<td></td>
</tr>
<tr>
<td>pure red cell aplasia (PRCA), parvovirus B19, 69</td>
<td></td>
</tr>
<tr>
<td>QiaGen system, 213</td>
<td></td>
</tr>
<tr>
<td>quality-adjusted life year (QALY), 356–357</td>
<td></td>
</tr>
<tr>
<td>quality assessment schemes (QAS), 222, 223–224</td>
<td></td>
</tr>
<tr>
<td>quality assurance, pathogen reduction, 254</td>
<td></td>
</tr>
<tr>
<td>quality control measures, 217</td>
<td></td>
</tr>
<tr>
<td>quality control samples, 222–223</td>
<td></td>
</tr>
<tr>
<td>stability, 223</td>
<td></td>
</tr>
<tr>
<td>statistical process monitoring, 223</td>
<td></td>
</tr>
<tr>
<td>validation, 224–225</td>
<td></td>
</tr>
<tr>
<td>quality improvement sources, 217</td>
<td></td>
</tr>
<tr>
<td>quality management, European Union legislation, 366</td>
<td></td>
</tr>
<tr>
<td>quantum dots, microarray sensitivity, 232</td>
<td></td>
</tr>
<tr>
<td>quarantine, samples, 225</td>
<td></td>
</tr>
<tr>
<td>radio-immune assay (RIA), 160</td>
<td></td>
</tr>
<tr>
<td>Radioimmunosuppression assay (RIPA), Chagas’ disease, 131</td>
<td></td>
</tr>
<tr>
<td>Rapid plasma reagin (RPR) tests, 166, 168</td>
<td></td>
</tr>
<tr>
<td>reactivity (screening), 219</td>
<td></td>
</tr>
<tr>
<td>falsely reactive results, 320</td>
<td></td>
</tr>
<tr>
<td>non-specific, 179–180, 312</td>
<td></td>
</tr>
<tr>
<td>reagents, assay design, 219</td>
<td></td>
</tr>
<tr>
<td>recombinant antigens, 227</td>
<td></td>
</tr>
<tr>
<td>recombinant coagulation factor concentrates, 284</td>
<td></td>
</tr>
<tr>
<td>recombinant immunoblot assay-3 (RIBA), anti-HCV testing, 174, 204</td>
<td></td>
</tr>
<tr>
<td>red blood cell(s)</td>
<td></td>
</tr>
<tr>
<td>inactivation systems, 107–109, 253</td>
<td></td>
</tr>
<tr>
<td>see also specific systems</td>
<td></td>
</tr>
<tr>
<td>reserved reduction, 68</td>
<td></td>
</tr>
<tr>
<td>reduction factors (pathogen reduction), 244, 245</td>
<td></td>
</tr>
<tr>
<td>fresh frozen plasma treatment, 246</td>
<td></td>
</tr>
<tr>
<td>prions, 287</td>
<td></td>
</tr>
<tr>
<td>regulatory environment, Europe, 363–368</td>
<td></td>
</tr>
<tr>
<td>organizations, 363–364</td>
<td></td>
</tr>
<tr>
<td>regulatory issues, 236–237</td>
<td></td>
</tr>
<tr>
<td>regulatory requirements</td>
<td></td>
</tr>
<tr>
<td>cost-effectiveness, 358</td>
<td></td>
</tr>
<tr>
<td>virus validation studies, 277–278</td>
<td></td>
</tr>
<tr>
<td>renal transplantation, 3K4I4 risk, 79</td>
<td></td>
</tr>
<tr>
<td>residual transfusion risks, 228, 312, 348</td>
<td></td>
</tr>
<tr>
<td>anti-HBC, 25–26</td>
<td></td>
</tr>
<tr>
<td>blood safety, Africa, 373</td>
<td></td>
</tr>
<tr>
<td>hepatitis B virus, 25–26, 26</td>
<td></td>
</tr>
<tr>
<td>HIV, 312</td>
<td></td>
</tr>
<tr>
<td>nucleic acid testing, 193–194, 200, 203, 204</td>
<td></td>
</tr>
<tr>
<td>pathogen reduction treatments, 242</td>
<td></td>
</tr>
<tr>
<td>resonance light scattering (RLS), microarray sensitivity, 232</td>
<td></td>
</tr>
<tr>
<td>respiratory viruses, 83–84</td>
<td></td>
</tr>
<tr>
<td>influenza virus, 84</td>
<td></td>
</tr>
<tr>
<td>severe acute respiratory syndrome, 84, 157, 284</td>
<td></td>
</tr>
<tr>
<td>Retrovirus Epidemiology donor Study (REDS), 27, 342, 345</td>
<td></td>
</tr>
<tr>
<td>retroviruses, 59–65</td>
<td></td>
</tr>
<tr>
<td>see also specific retroviruses</td>
<td></td>
</tr>
<tr>
<td>reverse passive haemagglutination assays (RPHA), 168</td>
<td></td>
</tr>
<tr>
<td>reverse transcription, nucleic acid testing, 211</td>
<td></td>
</tr>
<tr>
<td>riboflavin, 249, 253</td>
<td></td>
</tr>
<tr>
<td>ribonucleic acid, hepatitis C virus see hepatitis C virus (HCV)</td>
<td></td>
</tr>
<tr>
<td>risk assessments, 334–335, 343, 356</td>
<td></td>
</tr>
<tr>
<td>blood donor selection criteria, health damage, 155–156</td>
<td></td>
</tr>
<tr>
<td>calculations, 330–340</td>
<td></td>
</tr>
<tr>
<td>advantages, 338</td>
<td></td>
</tr>
<tr>
<td>false-negative tests, 331</td>
<td></td>
</tr>
<tr>
<td>infection surveillance, 331–333</td>
<td></td>
</tr>
<tr>
<td>limitations, 336–338</td>
<td></td>
</tr>
<tr>
<td>methods, 333–336</td>
<td></td>
</tr>
<tr>
<td>nucleic acid testing, 338</td>
<td></td>
</tr>
<tr>
<td>process error, 331</td>
<td></td>
</tr>
<tr>
<td>seroconversion, 332, 336–337</td>
<td></td>
</tr>
<tr>
<td>sero-negativity, 331</td>
<td></td>
</tr>
<tr>
<td>usage, 330–336</td>
<td></td>
</tr>
<tr>
<td>window periods, 333–334, 346–348, 349</td>
<td></td>
</tr>
<tr>
<td>categories, 341</td>
<td></td>
</tr>
<tr>
<td>definition, 341–342</td>
<td></td>
</tr>
<tr>
<td>fractionated products, 283–284</td>
<td></td>
</tr>
<tr>
<td>studies, prospective, 329–340</td>
<td></td>
</tr>
<tr>
<td>advantages, 338</td>
<td></td>
</tr>
<tr>
<td>limitations, 329–330</td>
<td></td>
</tr>
<tr>
<td>rewards, 330</td>
<td></td>
</tr>
<tr>
<td>risk characterization, 343–345</td>
<td></td>
</tr>
<tr>
<td>risk identification, 343–345</td>
<td></td>
</tr>
<tr>
<td>risk management, 341–361</td>
<td></td>
</tr>
<tr>
<td>autologous blood transfusion, 353</td>
<td></td>
</tr>
<tr>
<td>cardiac surgery, 345</td>
<td></td>
</tr>
<tr>
<td>case control studies, 344</td>
<td></td>
</tr>
<tr>
<td>communication, 343, 355–356</td>
<td></td>
</tr>
<tr>
<td>cost-effectiveness analysis, 356–357</td>
<td></td>
</tr>
<tr>
<td>definition, 342–343</td>
<td></td>
</tr>
<tr>
<td>direct measurement of risk, 345</td>
<td></td>
</tr>
<tr>
<td>infection rate vs. clinical outcomes, 356–351</td>
<td></td>
</tr>
<tr>
<td>interventions, 343</td>
<td></td>
</tr>
<tr>
<td>modelling, 345</td>
<td></td>
</tr>
<tr>
<td>prions see prion diseases</td>
<td></td>
</tr>
<tr>
<td>probability assignment, 342</td>
<td></td>
</tr>
<tr>
<td>psychometric studies, 354</td>
<td></td>
</tr>
<tr>
<td>risk assessment see risk assessments</td>
<td></td>
</tr>
<tr>
<td>risk per unit vs. risk per patient, 348, 350</td>
<td></td>
</tr>
<tr>
<td>simulation model, 342, 345–348</td>
<td></td>
</tr>
<tr>
<td>risk modelling, 345–348</td>
<td></td>
</tr>
<tr>
<td>risk perception, 353–354, 355</td>
<td></td>
</tr>
<tr>
<td>risk reduction measures, 351–353</td>
<td></td>
</tr>
<tr>
<td>robotic samples, 167</td>
<td></td>
</tr>
<tr>
<td>Roche Cobas Amplicore system, 209</td>
<td></td>
</tr>
<tr>
<td>Roche Cobas Core II system, 171</td>
<td></td>
</tr>
<tr>
<td>rodent cell lines, recombinant coagulation factor concentrates, 285</td>
<td></td>
</tr>
<tr>
<td>rolling circle amplification (RCA), microarray technology, 232, 235</td>
<td></td>
</tr>
<tr>
<td>S-303 see amotosalen (S-303)</td>
<td></td>
</tr>
<tr>
<td>S-303 clinical studies, 247</td>
<td></td>
</tr>
<tr>
<td>red cell treatment, 253</td>
<td></td>
</tr>
<tr>
<td>Safety ‘Tripod’ concept, Chagas’ disease, 132</td>
<td></td>
</tr>
<tr>
<td>Salmonella enterica, donor bacteriaemia, 88</td>
<td></td>
</tr>
<tr>
<td>sandflies, Leishmania infections, 126</td>
<td></td>
</tr>
<tr>
<td>sandwich assays see antigen(s)</td>
<td></td>
</tr>
<tr>
<td>Scansystem, 102–103, 105</td>
<td></td>
</tr>
<tr>
<td>Schreiber incidence/window period model, 26</td>
<td></td>
</tr>
<tr>
<td>Schwin, Horst, 270–271</td>
<td></td>
</tr>
<tr>
<td>Scottish National Blood Service (SNBS)</td>
<td></td>
</tr>
<tr>
<td>factor VIII production, 268</td>
<td></td>
</tr>
<tr>
<td>hepatitis C virus transmission, risk assessment, 284</td>
<td></td>
</tr>
<tr>
<td>scrapie, 141, 142</td>
<td></td>
</tr>
<tr>
<td>blood transfusion model, 144</td>
<td></td>
</tr>
<tr>
<td>screening, 227–238</td>
<td></td>
</tr>
<tr>
<td>bacteria challenges, 94–95</td>
<td></td>
</tr>
<tr>
<td>blood/blood components systems, 98–100</td>
<td></td>
</tr>
<tr>
<td>complexity, 228</td>
<td></td>
</tr>
<tr>
<td>cost, 228</td>
<td></td>
</tr>
<tr>
<td>developments, 228–229</td>
<td></td>
</tr>
<tr>
<td>features, 227</td>
<td></td>
</tr>
<tr>
<td>issues, 95</td>
<td></td>
</tr>
<tr>
<td>methods see screening methods</td>
<td></td>
</tr>
<tr>
<td>non-specific reactivity, 179–180</td>
<td></td>
</tr>
<tr>
<td>platelets, 101</td>
<td></td>
</tr>
<tr>
<td>quality see screening quality</td>
<td></td>
</tr>
<tr>
<td>regulatory issues, 236–237</td>
<td></td>
</tr>
<tr>
<td>safety, 228</td>
<td></td>
</tr>
<tr>
<td>serology, 227–228, 229, 235–236</td>
<td></td>
</tr>
</tbody>
</table>
Subject index

screening methods, 159–172, 227–228
assay performance, 165
future developments, 320–321
HBsAg testing, 14
history, 159–160
immunoassay options, 235–236
modern technologies, 169–171
impact on testing algorithms, 236–237
principles, 160–169
requirements, 159
see also confirmatory algorithms; individual
assays/techniques
screening quality, 217–226
assays see assays(s)
adherence systems, 222
donor selection, 218
haemovigilance, 226
lot release, 221–222
process, 217, 218
quality assessment schemes, 222, 223–224
quality control samples, 222–224
results assessment, 224–225
sensitivity, 218–219
specificity, 218–219
staff knowledge/skills, 225–226
strategies, 218–219
unsuitable donor identification, 225
validation, 224–225
SEN virus (SEN-V), 81–82
Seprion ligand assay, 149
serious adverse event/reaction, definition, 84
Serious Hazards of Transfusion (SHOT), 87, 89,
serious adverse event/reactio n, definition, 84
Seprion ligand assay, 149
SEN virus (SEN-V), 81–82
simian foamy virus (SFV), 1, 4–5, 6
signal amplification, microarrays, 232
small molecule microarrays, 233
solid phase immunoassay(s), 160–164, 227
antibody tests, 161–164
antigen tests, 160–161
antibody capture assays, 164
antigen sandwich assay, 162–163
antiglobulin tests, 162
competitive immunassays, 163
solvent detergent fresh frozen plasma (SDFFP),
242, 249
clinical studies, 251
clotting factor levels, 250
solvent detergent treatment, 272–274
development, 272–273
heat treatment and, 274
hepatitis A transmission, 11, 273–274
New York Blood Center, 272
virus validation studies, 282
Southern Cone Initiative (Resolution 04–3), Chagas’
disease, 128
SPRINT clinical study, 248–249
Standing Advisory Committee on Transfusion
Transmitted Infection (SACTTI), risk
assessment, 1, 2–3
Staphylococcus epidermidis, 89
statistical process monitoring (SPM)
quality control samples, 223
Westguard rules, 223
stool viral shedding, hepatitis A virus, 10
syphilis, 110–111
combination assays, 164
confirmatory algorithms, 176, 178
definition, 110
donor re-admission, 181
haemagglutination tests, 167
risk factors, 110
testing, 110
transfusion, estimated-risk, 111
Treponema pallidum, 110, 169, 345
window period, 110
system monitoring, nucleic acid testing, 214
TaqMan polymerase chain reaction (PCR), 185, 186
Thermus aquaticus (Taq), 184
thio nine, 249
third generation assays, HIV-1, 60
thrombin-antithrombin complexes, 251
thrombotic thrombocytopenic purpura, plasma
echange, 252–253
tissues
European Union legislation, 365–366
Treponema pallidum, 125, 159
Taxisplaasma gonidi, 125–126
life cycle, 125
seroprevalence rates, humans, 125
toxoplasmosis, 125–126
AIDS, 125
congenital, 125
diagnostic tests, 125, 126
transmission prevention, 126
transcription mediated amplification (TMA), 185–186
Procleix assay, 189, 209, 210
transfusion(s)
bedside checking procedures, 307–308
quality screening, 75–86
see also specific viruses
infection see post-transfusion infection
investigation
process, 306
transfusion-associated graft-versus-host disease
(TA-GVHD), pathogen reduction, 254
Transfusion medicine Epidemiology Review
(TMER), CID, 144
transfusion microbiology reference laboratory
functions, 181
quality screening process, 218
transfusion reactions, bacterial, 90
transfusion safety interventions, cost-effectiveness
analysis, 357–359
transfusion-transmissible infections (TTIs), 1–7, 240
annual risks, 350
clinically significant, 2
decline, 352
historical aspects, 1
issues, 7
medical interventions, 156–157
natural history, 323–327
screening see screening quality
residual risk, Africa, 375
SHOT reports, 388
species distribution, 119
UK hepatitis C national register see UK hepatitis C
national register
viruses associated, 1, 2–3, 344–345
see also specific infections
transfusion-transmitted malaria (TTM), 117–118
forms, 117
geographic distribution, 117, 118
historical aspects, 117
incidence, 118
infection period, 118
parasite harbouring, 118
transient aplastic crisis (TAC), parvovirus B19, 68–69
transmissible mink encephalopathy, 141
transmissible spongiform encephalopathy see prion
diseases
transplantation, renal, 79
transposition, definition, 363
travel, transfusion-transmissible infection risks, 156
Trophonema pallidum, 345
syphilis, 110
Trophonema pallidum haemagglutination assay
(TPHA), 169
triatomines, 128
Trypanosoma cruzi, 128–137
blood screening, 130, 159
characteristics, 128
haematophagous bugs, 128
life cycle, 128
post-transfusion infection investigation, 313
strains, 128
transmission, 128
viability, 129
trypanosomiasis, American see Chagas’ disease

cambridge.org
Subject index

TT virus (TTV) see torquetenovirus (TTV)
tyramide signal amplification (TSA), microarrays, 232

UK Blood Services Microbiology Kit Evaluation Groups see Kit Evaluation Groups (KEG)

UK Blood Transfusion Guidelines (2002), 180

UK hepatitis C national register, 323–327 comparative data sources, 324 enrolment, 323–324 information required, 324 morbidity, 324–326 mortality, 324–326 patient distribution, 325 patient follow-up, long-term, 324 recruitment, 323–324 as a resource, 326

ultraviolet light
UVA, 247–249 UVB, 249 virus inactivation, 270

vaccine/vaccination
haemophilia, 271 hepatitis A virus, 12 hepatitis B virus, 16 hepatitis e virus, 20 hepatitis transmission, 262 parvovirus B19, 69, 70 validation

Vereen Disease Reference Laboratory (VDRL), 166

Vidas immunoassay system, 171

Vietnamese blood donors, malarial screening, 122

Viral Activation Transfusion Study (VATS), 50

viral titres, pathogen reduction, 242, 244 virus(es)
emerging
fractionated products, 284 pathogen reduction treatments, 242 fractionated products, removal from, 275–277 adsorption, 275–276 precipitation, 275 recombinant coagulation factor concentrates elimination, 285 transmission, 285 see also specific viruses virus inactivation, 353 historical aspects, 270 processes

Vitros Eci immunoassay system, 171 von Willebrand factor cleaving protease, 252 levels, 251, 252

WA-1 infections, humans, 123

water baths, blood product contamination, 89

Western blot(s)
Chagas’ disease, 131 HIV-1, 61 KSHV detection, 78 nucleic acid testing vs., 203 prison removal, 286

Westguard rules, statistical process monitoring, 223

West Nile virus (WNV), 82–83, 284, 344

blood supply protection, 83 characteristics, 4.5–8.2–83 infection, 206, 207 nucleic acid testing, United States approach, 205 outbreak locations, 82 risks, 5 RNA detection, 83

transfusion, 83

window donations,” definition, 183

window period(s) (WP)
hepatitis A virus, 11 hepatitis B virus, 15 hepatitis C virus, 18 hepatitis E virus, 20 HIV, 62

human T-cell leukaemia viruses, 64

risk assessment, incidence calculation, 333–334, 346–348, 349

limitations, 347–348

Schober incidence, 26 syphilis, 110

World Health Organization (WHO), 363

Yersinia enterocolitica, 241
donor bacteraemia, 88

transfusion-transmission reduction strategies, 91

8Y treatment, 272